NEW DELHI, Dec 29: Dr Reddy’s Laboratories on Thursday said all claims against it in the antitrust litigation filed in the US, related to a prescription medicine Revlimid, used in treatment of multiple myeloma have been dismissed. In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Ltd and Dr Reddy’s Laboratories, Inc. Respectively, from the case. “All claims against the company in the litigation have now been […]